Bortezomib-Based Regimens for Newly Diagnosed Multiple Myeloma in China: A Report of 12-Year Real-World Data
Background: Improve the treatment quality might affect patients' efficacy and survival.Methods: Five hundred thirty multiple myeloma patients treated in four hematological centers in China from February 2006 to August 2018 were enrolled. General characteristics, treatment regimens and cycles, e...
Saved in:
Main Authors: | Jingsong He (Author), Donghua He (Author), Xiaoyan Han (Author), Gaofeng Zheng (Author), Guoqing Wei (Author), Yi Zhao (Author), Yang Yang (Author), Wenjun Wu (Author), Jiaping Fu (Author), Lihong Shou (Author), Hongwei Kong (Author), He Huang (Author), Zhen Cai (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2020-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Reduced weekly subcutaneous doses of bortezomib in combination with cyclophosphamide and dexamethasone for newly diagnosed multiple myeloma
by: Farzaneh Ashrafi, et al.
Published: (2020) -
Quadruplet regimen for newly diagnosed multiple myeloma is effective in the standard-risk subgroup but not in the high-risk subgroup
by: Jianghua Ding, et al.
Published: (2024) -
Cost-effectiveness of bortezomib for multiple myeloma: a systematic review
by: Chen W, et al.
Published: (2016) -
Bortezomib-Induced Reticular Eruption in Patient with Multiple Myeloma
by: Joseph Han, et al.
Published: (2023) -
Clinical Assessment of Bortezomib for Multiple Myeloma in Comparison with Thalidomide
by: Mitsutoshi Satoh, et al.
Published: (2011)